Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Jones

Showing results (91-100 of 191) with videos related to

Pageof 20
Sort By:
Journal of Medicinal Chemistry|March 6, 1992
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanoneC D Jones, L C Blaszczak, M E Goettel, et al.
Bioorganic & Medicinal Chemistry|June 18, 1998
Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2',3'-dideoxy-3'-C-(hydroxymethyl)-beta-D-erythropentofuranosyl] cytosineS C Mauldin, C J Paget, C D Jones, et al.
Journal of Medicinal Chemistry|August 1, 1984
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicityC D Jones, M G Jevnikar, A J Pike, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|March 21, 2008
Polarization splay as the origin of modulation in the B1 and B7 smectic phases of bent-core moleculesD A Coleman, C D Jones, M Nakata, et al.
Journal of Medicinal Chemistry|January 1, 1990
Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groupsC D Jones, M A Winter, K S Hirsch, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1994
Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteersR R Bowsher, J A Compton, J A Kirkwood, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.
Clinical Pharmacokinetics|August 19, 1999
Population pharmacokinetics. A regulatory perspectiveH Sun, E O Fadiran, C D Jones, et al.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
Pageof 20

Showing results (91-100 of 191) with videos related to

Sort By:
Pageof 20
Journal of Medicinal Chemistry|March 6, 1992
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanoneC D Jones, L C Blaszczak, M E Goettel, et al.
Bioorganic & Medicinal Chemistry|June 18, 1998
Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2',3'-dideoxy-3'-C-(hydroxymethyl)-beta-D-erythropentofuranosyl] cytosineS C Mauldin, C J Paget, C D Jones, et al.
Journal of Medicinal Chemistry|August 1, 1984
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicityC D Jones, M G Jevnikar, A J Pike, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|March 21, 2008
Polarization splay as the origin of modulation in the B1 and B7 smectic phases of bent-core moleculesD A Coleman, C D Jones, M Nakata, et al.
Journal of Medicinal Chemistry|January 1, 1990
Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groupsC D Jones, M A Winter, K S Hirsch, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1994
Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteersR R Bowsher, J A Compton, J A Kirkwood, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.
Clinical Pharmacokinetics|August 19, 1999
Population pharmacokinetics. A regulatory perspectiveH Sun, E O Fadiran, C D Jones, et al.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
Pageof 20